For several years, GSK has been evaluating a potentially disruptive technology, known as bioelectronics, that could in the future become a whole new class of treatments, complementing traditional drugs. Before allocating the resources to take this into mainstream medicine, they wanted to make sure they hadn’t missed any angles. So they appealed to InnoCentive’s global Solver community to identify the best “proof of principle” for these medicines.
Who Should Read This eBook?
If you’re a senior leader with managerial oversight or influence over your organization’s innovation initiatives or R&D function, this guide will provide you with fresh, new ideas and methods for tackling complex business problems and innovation challenges.